Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Gladman, D D
Bae, S C
Fortin, P R
Hanly, J G
Wallace, D J
Alarcón, G S
Bruce, I N
van Vollenhoven, R
Romero Diaz, J
MetadataShow full item record
CitationArthritis Care Res (Hoboken) 2014, 66 (9):1374-9
AbstractThe Medical Outcomes Study Short Form 36 (SF-36) is recommended to assess quality of life (QOL) in systemic lupus erythematosus (SLE). The aim of the current study was to assess QOL over time in the first 5 years of a multicenter inception cohort of patients with SLE.
An inception SLE cohort was assembled according to a standardized protocol between 2000 and 2012. In addition to clinical and laboratory assessments, patients completed the SF-36 at yearly intervals. Only patients who had ≥5 completed QOL questionnaires were included in these analyses. Generalized estimating equation models were run separately for each of the 8 subscales and for the physical and mental component summary scores, adjusting for repeated measures by patients.
A total of 495 patients were included. The mean ± SD disease duration at the first visit was 5.3 ± 4.1 months. The mean ± SD age at enrollment was 35.8 ± 13.2 years. All 8 subscales and the 2 summary scores showed improvement in the first 2 years from enrollment. Between years 2 and 5, none of the subscales or summary scores showed any change. Minimum clinically important improvement was achieved by 35-56% of the patients and was influenced by demographic and disease factors.
Unlike late-stage lupus, where QOL is stable over time, in patients with early disease, all subscales improve in early followup up to 2 years. Therefore, the SF-36 may be a sensitive outcome measure in early disease in patients with SLE.
DescriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the page
RightsArchived with thanks to Arthritis care & research
- Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?
- Authors: Touma Z, Gladman DD, Ibañez D, Urowitz MB
- Issue date: 2011 Sep
- Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort.
- Authors: Urowitz MB, Gladman DD, Ibañez D, Fortin PR, Bae SC, Gordon C, Clarke A, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guerrero J, Wallace DJ, Ginzler E, Alarcón GS, Merrill JT, Bruce IN, Sturfelt G, Nived O, Steinsson K, Khamashta M, Petri M, Manzi S, Ramsey-Goldman R, Dooley MA, van Vollenhoven RF, Ramos M, Stoll T, Zoma A, Kalunian K, Aranow C
- Issue date: 2012 Jan
- Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE.
- Authors: Devilliers H, Amoura Z, Besancenot JF, Bonnotte B, Pasquali JL, Wahl D, Maurier F, Kaminsky P, Pennaforte JL, Magy-Bertrand N, Arnaud L, Binquet C, Guillemin F, Bonithon-Kopp C
- Issue date: 2015 May
- Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course.
- Authors: Alarcón GS, McGwin G Jr, Uribe A, Friedman AW, Roseman JM, Fessler BJ, Bastian HM, Baethge BA, Vilá LM, Reveille JD
- Issue date: 2004 Jun 15
- Long-term outcome of early neuropsychiatric events due to active disease in systemic lupus erythematosus.
- Authors: Wang M, Gladman DD, Ibañez D, Urowitz MB
- Issue date: 2012 Jun